ampelopsin has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JF; Du, YH; Feng, J; He, GQ; Liu, Y; Liu, YJ; Wang, JX; Wang, KJ; Zhang, W; Zheng, M | 1 |
| Liang, J; Lindemeyer, AK; López-Valdés, HE; Martínez-Coria, H; Olsen, RW; Shao, XM; Shen, Y | 1 |
2 other study(ies) available for ampelopsin and Cognition Disorders
| Article | Year |
|---|---|
Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents; Brain; Cell Line, Transformed; Cognition Disorders; Cytokines; Disease Models, Animal; Encephalitis; Flavonols; Gene Expression Regulation; Humans; Inflammasomes; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Mutation; NLR Family, Pyrin Domain-Containing 3 Protein; Presenilin-1; RNA, Messenger; Time Factors | 2018 |
Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anxiety; Cognition Disorders; Disease Models, Animal; Flavonols; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic | 2014 |